Convergent Therapeutics is a clinical-stage biotechnology company developing targeted radiopharmaceuticals to treat cancer.
Radioantibodies precisely target and kill cancer cells while sparing healthy tissues. (A) Proprietary antibodies are linked to a radionuclide, such as actinium-225 (225Ac), to create a highly potent therapy. (B) Once a radioantibody locates and binds to its target on the surface of a cancer cell, (C) it is internalized into the tumor cell, (D) thereby delivering its radioactive payload directly to the nucleus of the cell and causing irreparable DNA damage that kills the cell.
Lead Clinical Candidate
CONV01-α is a proprietary, best-in-class radioantibody targeted to Prostate-Specific Membrane Antigen (PSMA), an antigen expressed on the surface of almost all prostate cancer cells.
CONV01-α is linked to a powerful radionuclide called 225Ac. 225Ac releases alpha particles which kill cancer cells through DNA double strand breaks. Unlike other radioactive sources, alpha particles deliver high-energy radiation over very short distances, thereby minimizing radiation exposure to healthy neighboring cells and tissues. Pairing highly selective antibodies with such a powerful yet precise payload offers the ideal combination to treat many types of cancers.
CONV01-α has demonstrated clinical efficacy and safety in Phase I/II prostate cancer clinical trials
In a Phase 1 Single Ascending Dose trial of CONV01-α in men with metastatic castration-resistant prostate cancer (mCRPC), most patients responded and 44% of the patients experienced a greater than 50% decline in prostate-specific antigen (PSA) levels after receiving only a single dose of CONV01-α. The patients enrolled were heavily pre-treated with prior androgen deprivation therapy, at least one androgen receptor signaling inhibitor, taxane chemotherapy, and almost half of the patients received prior 177Lu-PSMA-radioligand and more than a quarter received prior radium-223. PSMA PET was performed prior to treatment but positivity was not used to pre-select patients.
CONV01-α is being explored as a backbone therapy across treatment modalities
Building on the success in several clinical trials, Convergent Therapeutics is already working with industry and academic partners to explore the potential of alpha-based radioantibodies as backbone therapies to cancer treatment.